Showing results (141-150 of 270) with videos related to
Sort By:
Pageof 27
JCO Precision Oncology|January 5, 2023
HRAS Mutations Define a Distinct Subgroup in Head and Neck Squamous Cell CarcinomaNiamh Coleman, Kathrina L Marcelo, Julia F Hopkins, et al.Frontiers in Oncology|April 9, 2024
Case report: Molecular profiling facilitates the diagnosis of a challenging case of lung cancer with choriocarcinoma featuresHui Li, Xin Hu, Matthew S Ning, et al.Nature Communications|December 8, 2025
Precise diagnosis of small invasive pulmonary nodules driven by single-cell immune signatures in peripheral bloodYang Xia, Yin Zhu, Sai Zhang, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 23, 2023
Poziotinib in Treatment-Naive NSCLC Harboring HER2 Exon 20 Mutations: ZENITH20-4, A Multicenter, Multicohort, Open-Label, Phase 2 Trial (Cohort 4)Robin Cornelissen, Arsela Prelaj, Sophie Sun, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 6, 2026
Genomic Profiling of Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer Post-Progression on First-Line Osimertinib: Phase II ORCHARD StudyHelena A Yu, Kwan Ho Tang, Aleksandra A Markovets, et al.Clinical Lung Cancer|October 31, 2025
Actionable Gene Alterations in Resected Non-Small Cell Lung Cancer: Primary Results From the AGA-R StudyIlaria Attili, Gloria Pellizzari, Luca Bertolaccini, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 3, 2023
IL6 Mediates Suppression of T- and NK-cell Function in EMT-associated TKI-resistant EGFR-mutant NSCLCSonia A Patel, Monique B Nilsson, Yan Yang, et al.Oncology and Therapy|October 11, 2025
The Phase 2b COPERNICUS Study of Subcutaneous Amivantamab with Lazertinib as First-Line Treatment, or with Chemotherapy as Second-Line Treatment, for EGFR-Mutated Non-Small Cell Lung Cancer: a VodcastBalazs Halmos, Narjust Florez, Sarah Goldberg, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 14, 2023
CD73 Inhibitor Oleclumab Plus Osimertinib in Previously Treated Patients With Advanced T790M-Negative EGFR-Mutated NSCLC: A Brief ReportDong-Wan Kim, Sang-We Kim, D Ross Camidge, et al.Clinical Lung Cancer|April 25, 2022
Safety of Tepotinib in Patients With MET Exon 14 Skipping NSCLC and Recommendations for ManagementRemi Veillon, Hiroshi Sakai, Xiuning Le, et al.Pageof 27